New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:11 EDTADHDAlcobra completes patient recruitment in Phase III clinical trial of MDX
Alcobra announced that recruitment of patients has been completed in the company's Phase III clinical trial of Metadoxine Extended Release, or MDX, in adult ADHD patients. The study is a 300-patient, randomized, placebo-controlled trial conducted at 18 sites in the United States and 2 in Israel. Patients were randomized to receive either 1400 mg MDX or placebo over 6 weeks following a 2-week screening period. The primary endpoint is the Conners' Adult ADHD Rating Scale, or CAARS-INV, a widely accepted clinical measure of the presence and severity of ADHD symptoms. Secondary endpoints include the computerized TOVA, or Test of Variables of Attention, which was also used in the previous Phase 2 studies, as well as safety assessments and additional exploratory endpoints.
News For ADHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 10, 2014
11:18 EDTADHDOptions with decreasing implied volatility
Subscribe for More Information
October 8, 2014
10:46 EDTADHDOptions with decreasing implied volatility
Subscribe for More Information
06:00 EDTADHDStocks with implied volatility below IV index mean; ADHD LULU
Stocks with implied volatility below IV index mean; Alcobra (ADHD) 123, lululemon (LULU) 35 according to iVolatility.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use